Summary of antitumor effect generated by αGC-loaded A20 vaccination
| Vaccination model . | Survival rate, no. (%) . | |
|---|---|---|
| First tumor challenge . | Second tumor challenge . | |
| Prophylactic | ||
| Nil | 0/20 (0) | 0/14 (0) |
| A20/veh | 0/19 (0) | — |
| A20/αGC | 19/19 (100) | 19/19 (100) |
| Therapeutic, day =5 | ||
| Nil | 0/15 (0) | 0/10 (0) |
| A20/veh | 0/16 (0) | — |
| A20/αGC | 7/16 (44) | 7/7 (100) |
| Therapeutic, day =10 | ||
| Nil | 0/10 (0) | ND |
| A20/veh | 0/10 (0) | ND |
| A20/αGC | 2/10 (20) | ND |
| Vaccination model . | Survival rate, no. (%) . | |
|---|---|---|
| First tumor challenge . | Second tumor challenge . | |
| Prophylactic | ||
| Nil | 0/20 (0) | 0/14 (0) |
| A20/veh | 0/19 (0) | — |
| A20/αGC | 19/19 (100) | 19/19 (100) |
| Therapeutic, day =5 | ||
| Nil | 0/15 (0) | 0/10 (0) |
| A20/veh | 0/16 (0) | — |
| A20/αGC | 7/16 (44) | 7/7 (100) |
| Therapeutic, day =10 | ||
| Nil | 0/10 (0) | ND |
| A20/veh | 0/10 (0) | ND |
| A20/αGC | 2/10 (20) | ND |
Data are pooled from 3 prophylactic and 3 therapeutic experiments.
ND indicates not determined; —, not applicable.